From Globe Newswire:

Esperion Therapeutics has announced the pricing of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, with an additional 30-day option granted to the underwriters. The gross proceeds from the offering are expected to be approximately $85.1 million, with the offering closing on January 23, 2024. The net proceeds will be used to fund commercialization efforts and research and clinical development, alongside general corporate purposes.

For more information, visit esperion.com and esperionscience.com and follow them on Twitter at twitter.com/EsperionInc.

Esperion Therapeutics has appointed Jefferies LLC as the sole book-running manager for the offering. A registration statement has also been filed with the SEC and was declared effective on April 26, 2022. The offering will be made by means of a prospectus supplement and accompanying prospectus, which can be obtained from the SEC’s website or Jefferies LLC directly.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.



Read more: Esperion Announces Pricing of $85.1 Million Public Offering